KIT and gastrointestinal stromal tumor: GIST is considered a paradigm for precision oncology because imatinib, which specifically targets KIT/PDGFR driver mutations, has drastically improved the median overall survival (mOS) to around 5 years as well as the quality of life of patients diagnosed with metastatic GIST, which was once recognized as a devastating chemotherapy-resistant cancer with a dismal prognosis of less than 6 months [3].